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The key intermediate 1-[4-piperidyl]-3,4-dihydro-6,7-dimethoxyisoquinoline 4 is prepared by the
Bischler Napieralski cyclisation of 1-[1-(3,4-dimethoxyphenyl)]-2-(I-acetyl-4-carbomyl piperidino)-
ethane 2 followed by the acidic hydrolysis of the intermediate 3 thus obtained. Condensation of 4 with
r-chloro-(4-fluorophenyl) butyrophenone furnishes 1-[4-(6,7-dimethoxy-3,4-dihydroisoquinoline-l-yl)
piperidino]-3-(4-fluorobenzoyl)propane 5 which on reduction with NaBH4 and H2 (Pd/c) give the
reduced derivatives 6 and 7 respectively. Condensation of 9 with methylvinylketone and 2-
bromopropionyl chloride yields 10 and 11 respectively; The condensation of 11 with substituted phenols
and thiophenol affords the aryloxy/thioaryloxy compounds 12-14. Reduction of 12 with lithium
aluminium hydride give the aminoethyl derivative 15. Among these compounds 5,10 and 14 showed
potent CNS depressant activity.
Identification of the pharmacophore and its
verification has always been the subject of interest
to medicinal chemist. A careful examination of
neuroleptics belonging to different chemical
classes viz. butyrophenones, phenothiazenes,
benzamides, benzocycloheptapyridoisoquinolines
etc. revealed that they have common substructure
in which aromatic ring is separated from the
tertiary (neuroleptic) nitrogen by 4 atoms
especially by 4-carbon atoms \.s.
The QSAR studies in 2-substituted-
1,2,3,4,6,7,12, 12a-octhahydropyrazino [2', 1':6,1]
pyrido (3,4-b) indoles", a new class of CNS
depressants and our earlier work on 1-(r-
substituted propyl)-4-(4-fluorobenzoyVfluoro-
benzylhydryl) piperidines, also showed that this
substructure in which phenyl ring is separated
from the tertiary nitrogen preferably by 4 carbon
atoms has positive contribution towards
neuroleptic activity'. In order to further examine
the importance of this pharmacophore, different 1-
substituted-4-[4-flourobenzoyV6,7-dimethoxy-3,4-
dihydroisoquinolyl)piperidines and related
compounds have been synthesized and evaluated
for their central nervous system (CNS) and
cardiovascular system (CVS) disorders. The results
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of these studies are described in this paper.
Bischler Napieralski cyclisation of 1-[1-(3, 4-
dimethoxyphenyl) ]-2-( l-aryl-4-carbomyl piperidi-
no) ethane 2 obtained by the condensation of 1-
acetylisonipecotic acid chloride 1 with 2-(3,4-
dimethoxyphenyl)ethylamine, afforded 1-[1-
acetyl-4-piperidino]-3, 4-dihydro-6, 7-dimethoxy-
isoquinoline 3. Acid hydrolysis of 3 gave




which on reduction with NaBH. and PdlC gave the
tetrahydro derivatives 6 and 7 respectively
(Scheme I). Though these compounds may be
mixture of diastereoisomers but it was difficult to
decide as they were homogenous on lLC and the
NH-CH proton was merged with other protons in
the region (3.3-2.15) and (3.6-1.9) in 6 and 7
respectively.
The other intermediate 4-(4-fluorobenzoyl)-
piperidine 9 was prepared essentially according to
literature procedure' starting from isonipecotic
acid. The acid on acetylation with acetic anhydride
gave the N-acetyl isonipecotic acid which on
treatment with thionyl chloride yielded the acid
chloride 1. The reaction of 1 with fluorobenzene
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under Friedal Craft conditions afforded the 1-
acetyl-4-(4-flourobenzoyl)piperidine 8 which on
acidic hydrolysis gave the 4-(4-fluorobenzoyl)
piperidine 9. Condensation of 9 with
methylvinylketone afforded 1-[4-(4-fluorobenzoyl)
piperidin-l-yl]-2-acetyl ethane 10 and its reaction
with 2-bromopropionyl chloride" gave 1-[4-(4-
fluorobenzoyl) piperidin-l-ylj-l-oxo-z-bromopro-
pane 11. The latter on condensation with
substituted phenols and thiophenol yielded the
required derivatives 12-14 respectively. The 3-
acetamidophenoxy derivative 12 on reduction with
lithium aluminium hydride afforded the
corresponding aminoethyl derivative 15
(Scheme II).
Results and Discussion
The compounds 5-15 were tested for their





avoidence responses in rats.
Male Swiss mice (4-5 for each compound) of
CDR! colony, each weighing 15-20 g, were used
for various neurological test which mainly
employed postural reactions. The results are
surnmarised in Table 1. No blockade of grasping"
and righting" reflexes, auditory startle" and head
shaking" were produced by these drugs. Pupillary,
corneal and flexion reflexes":" and placing
reactions" were mildly blocked in some cases.
Male charles foster rates (CDR! colony) weighing
140-160 g, were trained to climb a pole to avoid
foot-shock according to method of Cook &
WeidlylS using a pole climbing apparatus (Techno
Electronics, Lucknow) with provision for applying
the conditioned (Tone, 50 Hz) and unconditioned
stimuli (foot-shock, 1.0 mA) for a period of 15 sec
each. The trial ended either after the animal
responded by jumping on the pole or after 30 see







1) X=O R =4-NHAC_, I
14, X = 5 , R = 4-NHACScheme II
whichever event occurred earlier.
These compounds were also tested to their effect
on blood pressure and respiration in anaesthesised
cats by administering different doses. . The
significiant results are described in Table I.
The compounds mainly exhibited tranquilizing
and anxiolytic activity by blocking SCRI6 and
CARI7 in the following order 5=10> 14> 12 > 15.
Among these compounds the compounds 5 and 10
having the required substructure where phenyl ring
is separated from the basic nitrogen by 4-carbon
atoms exhibited the most significant tranquilizing
activity. The relatively less activity shown by other
compounds with the same pharmacophore may be
due to variation in their overall lipophilicity. In
addition to CNS activity the compounds 10 and 12
also exhibited significant hypotensive activity.
Experimental Section
Melting points are uncorrected and were taken
in an electrically heated apparatus. All the
compounds were routinely checked for their
structure. IR (vrnax in cm') spectra were recorded









% fall in Duration
B.P. (min.)
(mmHg)
5 10 100 60
10 10 100 60 70 75
12 20 60 20 54 15
14 10 100 40
15 10 20 20
on Perkin-Elmer infrared models 137, 157 and
177, PMR spectra on a Varian 60D or Perkin-
Elmer R-32 instrument using 1MS as internal
reference (chemical shift in 0, ppm and j values in
Hz) and mass spectra on Jeol-JMS D-300
spectrometer. Homogenity of the compounds was
checked by TLC on silica gel G plates and the
spots were located either by spraying with KMn04
solution or by exposing to iodine vapours.
1-[1-(3, 4-Dimethoxyphenyl) ]-2-(I-aryl-4-car-
bomoylpiperidino)-ethane 2. A mixture of 1 (4.3
TRIPATIll etal. :SYNTIIESIS & SAR IN PIPERIDINES 59
g, 0.022 mol), 2-(3,4-dimethoxy-phenyl) ethyl-
amine (3.6 g, 0.20 mol), TEA (5 mL) in dry TIIF
(50 mL) was refluxed for 4 hr at 80°C. The
reaction mixture was concentrated, diluted with
HzO (30 mL) and extracted with cn.ci, (3x30
mL). The ca.ci, extracts were dried (NazS04),
concentrated to give 2 which was purified by
column chromatography using silica gel as
stationary phase and methanol: chloroform (2:98)
as eluant and crystallised with ether, yield 4.7 g
(62%), m.p. 118°C; IR (KBr): 3300, 2900, 1640,
1560, 1520, 1440, 1360, 1340, 1270, 1240, 1220,
1200, 1150, 1030; PMR (CDCI3): 6.73-6.51(m, 3H,
ArH), 3.77(s,6H, 2xOCH3), 3.60-2.20(m, IOH,
NCHz.ArCHz, COCH), 2.00(s,3H,COCH3), 1.80-
1.50 (m,4H,CHz) (Found: C, 64.32; H, 7.61; N,
8.15. Calcd for CIsHz604Nz(Mol. wt. 334): C,
64.67; H, 7.78; N, 8.38%).
1-[I-Acetyl-4-piperidino]-3, 4-dihydro-6, 7-di-
methoxyisoquinoline 3. A solution of 2 (0.5 g,
0.0016 mol) in POCl3 was refluxed for 3 hr at
110°C. The reaction mixture was cooled and
poured into crushed ice (40 g). It was basified with
6N NaOH and the separated oil was extracted with
ethyl acetate (3x20 mL), dried (NazS04) and
concentrated to give an oil which in trituration
with hexene gave 3 as crystalline solid, yield 300
mg (64%), m.p. 128°C; IR (KBr): 2950, 2850,
1650, 1580, 1520, 1460, 1400, 1380, 1360, 1320,
1280, 1240, 1220, 1180, 1100, 1040, 1010, 990,
970, 900, 830, 790; PMR(CDCI3): 6.93 (s, IH, Ar-
H), 6.65 (s, IH, ArH), 4.57 (m, IH, CH), 3.85 (s,
6H, 2xOCH3), 3.70-2.40 (m, 8H, NCHz, ArCHz),
2.05 (s, 3H, COCH3), 2.00-1.70 (m, 4H, CHz)
(Found: C, 68.12; H, 7.27; N, 8.57. Calcd for
CIsHz403Nz(Mol. Wt 316): C, 68.35; H, 7.59; N,
8.86%).
1-[4-Piperidyll-3,4-dihydro-6, 7-dimethoxyiso-
quinoline 4. A solution of 3 (3.16 g, 0.01 mol) in
6N HCI (40 mL) was refluxed at 100°C for 14 hr.
It was cooled and basified with 6N NaOH. The
solution was extracted with dichloromethane, dried
.(NazS04) and concentrated to give a brown viscous
oil which was purified by, passing it through silica
gel column in methanol: chloroform (5:95), and
concentrating the organic solvent, yield 2.6 g
(95%); IR (neat): 2900, 1620, 1580, 1460, 1380,
1340, 1280, 1240, 1210, 1180, 1160, 1100, 1040,
960, 880, 820, 760; PMR (CDCI3): 6.83 (s, IH
ArH), 6.50 (s, IH, ArH), 4.50 (m, IH, CH), 3.7 (s,
6H, 2'xOCH3), 3.67-3.20 (m, 2H, Ar-CHz), 3.10-
2.30 (m, 6H, N-CHz), 1.80-1.40 (m, 4H, CHz)
(Found: C, 69.86; H, 7.93; N, 10.12. Calcd for




mixture of 4 (2.74 g, 0.01 mol), r-chloro-4-
fluorobutyrophenone (2.0 g, 0.01 mol), KZC03
(1.56 g, 0.011 mol) and NaI (0.1 g, 0.0006 mol)
dry acetone (50 mL) was refluxed for 30 hr at
70°C and the reaction mixture was filtered. The
filtrate was concentrated and the residue was
diluted with HzO (20 mL). It was extracted with
ether (2x30 ml), dried (Na2S04), concentrated and
triturated with hexane to give 5 which was
crystallised with ether-hexane, yield 2.19 g (50%),
m.p. 138°C; IR(KBr): 2900, 1680, 1600, 1520,
1480, 1410, 1380, 1360, 1320, 1280, 1240, 1200,
1160, 1080, 1040, 980, 960, 900 860, 840, 780;
PMR(CDCI3): 8.10-7.77 (m, 2H, ArH), 7.20-6.56
(m, 4H, ArH), 3.80 (s, 6H, 2xOCH3), 3.70-2.70 (m,
6H, CH2),2.60-0.90 (m, 13H, rest CH2) (Found: C,
70.96; H, 6.87; N, 6.15. Calcd. for C26gH3103NzF
(Mol Wt 438): C, 71.43; H, 6.97; N, 6.39%).
1-[4-(6, 7-Dimethoxy-l, 2, 3, 4-tetrahydro-6,
7-dimethoxyisoquinolin-l-yl)]-3-[I- (4-fluoro-
benzhydryl)] propane 6. NaBH4 (0.4 g, 0.0074
mol) was slowly added to a stirred solution of 5
(0.438 g, 0.001 mol) in methanol (30 mL) at O°C.
The reaction mixture was stirred at 30°C for 48 hr,
concentrated, diluted with HzO (25 mL) and
extracted with ether (3x25 mL). The combined
ether extracts were dried (NazS04) and
concentrated to give 6 as viscous oil, yield 2.92 g
(66%), characterised as its HCI salt, m.p. 174°C;
IR(neat free base): 3500, 3000, 1620, 1220, 860,
780; PMR (CDCI3, free base): 7.33-6.40 (m 6H,
ArH), 4.40 (m, IH, OCH), 3.67:(s, 6H, 2xOCH3),
(3.30-2.15 (m, IIH, NCHz, ArCHz, HNCH), 1.80-
0.95 (m, 9H, CHz, CH) (Found: C, 77.27; H, 7.81;
N, 6.19. Calcd for CZ6H3s03NzF(Mol. Wt 442): C,
77.58; H, 7.91; N, 6.33%).
1-[4-(6,7-Dimethoxy-l, 2, 3, 4-tetrahydroiso-
quinolin-l-yl)pip-eridino ]-3- [4-fluorobenzo-yl)-
propane 7. A solution of 5 (0.438 g, 0.001 mol) in
ethanol (50 mL) was hydrogenated in the presence
of Pd/C (0.4 g) at 50 psi for 7 hr. The catalyst was
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removed by filtration and filtrate was concentrated
to give 7, crystallised with methanol-ether, yield
0.35 g (79%), m.p.188°C; IR (KBr): 3500, 3000,
1700, 1620, 1540, 1460, 1270, 1240, 1180, lBO,
1020, 1000, 980, 8.20; PMR(CDCI3): 8.00-7.70
(m, 2H, ArH), 7.20-6.60 (m, 4H, ArH), 3.67 (s,
6H, 2xOCH3), 3.60-1.90 (m, 13H, NCH2, ArCH2,
COCH2, NHCH), 1.70-0.9 (m, 7H, CH2, CH)
(Found: C, 70.74; H, 7.17; N, 6.12 Calcd for
C26H3303N2F(Mol. Wt 440): C, 70.90; H, 7.50; N,
6.36%).
1-[4-Fluorobenzoyl)piperidin-l-yl]-2-acetyl
ethane 10. A mixture of 9 (2.07 g, 0.01 mol)
methyl vinyl ketone (0.7 g, 0.01 mol) in DMF (25
mL) was stirred at room temp for 8 hr. It was
diluted with H20 (40 mL) and extracted with
chloroform. The organic layer was washed with
H20 (3x25 mL), dried (Na2S04) and concentrated
to give an oil which was purified by passing
through silica column using methanol:chloroform
(2:98) as eluant, yield 1.24 g (45%), m.p. 61°C;
IR(KBr): 2940, 2800, 1700, 1660, 1640, 1600,
1500, 1420, 1360, 1160, 950; PMR (CDCI3):8.10-
7.80 (m, 2H, ArH), 7.30-6.80 (m, 2H, ArH), 4.01-
3.90 (m, IH, CH), 3.60-2.90 (m, 4H, N-CH2), 2.00-
2.60 (m, 2H, NCH2), 2.20 (s, 3H, CH3), 2.10-1.80
(m, 6H, CH2) (Found: C, 62.34; H, 7.71; N, 4.96.
Calcd for Cl6H2002NF(Mol. Wt 277): C, 62.09; H,
7.22; N, 5.05%).
1-[4-(4-Fluorobenzoyl)piperidin-I-yl]-I-oxo-2-
bromopropane 11 A mixture of 9 (1.03 g, 0.005
mol), 2-bromopropionyl chloride (0.85 g, 0.005
mol) and triethylamine (0.7 g, 0.006 mol) in dry
THF (50 mL) was refluxed for 5 hr at 90°C,
concentrated and diluted with H20 (50 mL). The
aq. layer was extracted with chloroform (3x30
mL). The combined organic layer was washed with
5% NaOH (lxl5 mL) followed by H20 (2x30 ml),
dried (Na2S04) and concentrated to give 11 as a
brown oil, yield 0.94 g (55%); IR(neat): 3000,
2940, 2860, 1680, 1630, 1600, 1500, 1450, 1400,
1350, 1220, 1010, 960, 740; PMR (CDC13):8.20-
7.80 (m, 2H, ArH), 7.40-7.00 (m, 2H, ArH), 4.60
(q, IH, CH3 CH), 4.00-3.90 (m, IH, CH), 3.70-
2.50 (m, 4H, NCH2), 2.20-1.00 (m, 4H, CH2), 1.75
(d, 3H, CH3) (Found: C, 66.34; H, 6.51; N, 5.90.
Calcd for C1sH1702NFBr(Mol. Wt 342) : C, 66.11;
H, 6.48; N, 5.78%).
1-[4-(4-Fluorobenzoyl)piperidine-I-yl)-I-oxo-
2-[3-acetamidophenoxy]propane 12. A mixture
of3-acetamidophenol (1.51 g, 0.005 mol) in NaOH
(0.4 g in 2 mL), 11 (1.71 g, 0.005 mol) and ethanol
was refluxed for 48 hr at 900C. The reaction
mixture was filtered and the filtrate was
concentrated and chromatographed on silica
column using 1% MeOH in chloroform as eluant
to give 12 as an white solid, yield 1.38 g (67%),
m.p. 92°C; IR(KBr): 3300, 2920, 1650, 1600,
1500, 1450, 1400, 1360, 1300, 1240, 1080, 960,
820; PMR(CDC13):8.00-7.70 (m, 5H, 2x2 NCH2&
CH), 3.60-2.90 (m, 4H, CH2), 2.05 (s, 3H, CH3),
1.55 (d, 3H, CH3) (Found: C, 66.99; H, 6.06; N,
6.79. Calcd for C23H2S04N2F(Mol. Wt 412): C,
66.83; H, 5.94; N, 6.81%).
Compounds 13 and 14 were synthesized by a
similar method and their characterisation data are
given below: 13: C23H2S04N2F,m.p. 115°C, yield
69%; 14: C23H2S03N2SFm.p. 88°C, yield 64%.
1-[4-(4-Fluorobenzhydryl)piperidin- l-yl)-2-
(3-ethylaminophenoxy)-propane 15. A mixture
of 12 (0.412 g, 0.001 mol(, LAH (0.2 g) in dry
THF (50 mL) was refluxed under stirring for 8 hr.
LAH was neutralised with 10% KOH solution and
reaction mixture was filtered and the filtrate was
concentrated to give 15 which was
chromatographed on silica gel column using
CHCL3 MeOH (96:4) as eluant. The eluate on
concentration gave a brownish oil, yield 0.15 g
(36%); IR(neat): 3300, 3000, 2940, 1600, 1500,
1240, 1200, 1140, 1060, 720; PMR (CDCI3): 7.40-
6.90 (m, 9H, ArH, NH), 4.60-4.40 (m, IH, CH3
CH), 4.35 (dd, IH, CHOH), 3.70-3.60 (m, IH,
CH), 3.20-2.00 (m, 6H, NCH2), 2.70-2.40 (m, 6H,
CH2), 2.10-1.90 (s, IH, OH), 1.40-1.10 (m, 6H,
CH3)(Found: C, 71.63; H, 7.90; N, 6.94. Calcd for
C23H3102N2F(Mol. Wt 386): C, 71.50; H, 8.03; N,
7.25%).
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